SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer

Jin Li(Shanghai East Hospital), Shukui Qin(81th Hospital of PLA), Hongming Pan(Sir Run Run Shaw Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Feng Zhang(National Space Science Center), Fuxiang Zhou(Wuhan University), Jianping Xiong(Nanchang University), Chunyi Hao(Peking University), Yuxian Bai(Harbin Medical University), Tao Zhang(First Affiliated Hospital of Jinan University), Juan Zhang(Hebei Medical University), Xiaoyan Lin(Fujian Medical University), Zhang Zhang(Sun Yat-sen University), Zhendong Chen(Anhui Medical University), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Yajin Chen(Sun Yat-sen University), Zhiqiang Meng(Shanghai Medical College of Fudan University), Yabing Guo, Fan Yu(BeiGene (China)), Weijia Fang(Zhejiang Cancer Hospital), Xin Li(BeiGene (China)), Zhenggang Ren(Ministry of Education of the People's Republic of China)
Cancer Immunology Immunotherapy
September 5, 2024
10.1007/s00262-024-03806-2
Cited by 15

Related Papers

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775